

# Xiaomin Niu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7697772/publications.pdf>

Version: 2024-02-01

31  
papers

818  
citations

567281

15  
h-index

501196

28  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1488  
citing authors

#	ARTICLE	IF	CITATIONS
1	FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelialâ€‘mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. <i>Oncogene</i> , 2018, 37, 5340-5354.	5.9	123
2	Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer. <i>Analytica Chimica Acta</i> , 2017, 982, 84-95.	5.4	107
3	Facile preparation of salivary extracellular vesicles for cancer proteomics. <i>Scientific Reports</i> , 2016, 6, 24669.	3.3	52
4	The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. <i>Cancer Letters</i> , 2018, 423, 36-46.	7.2	52
5	The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. <i>FEBS Letters</i> , 2014, 588, 3000-3007.	2.8	47
6	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutationâ€‘Positive Nonâ€‘Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5173-5180.	7.0	47
7	A Study of Ethnic Differences in TGFÎ²1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Nonâ€‘Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1668-1675.	1.1	39
8	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. <i>Oncotarget</i> , 2016, 7, 18394-18402.	1.8	38
9	The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2014, 7, 387.	2.0	24
10	Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, e157-e159.	1.1	24
11	Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 62.	17.0	24
12	Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 839-847.	1.9	23
13	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Nonâ€‘Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e21-e24.	1.1	23
14	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. <i>Current Treatment Options in Oncology</i> , 2017, 18, 71.	3.0	22
15	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. <i>Lung Cancer</i> , 2018, 123, 83-86.	2.0	19
16	Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population. <i>Journal of Thoracic Oncology</i> , 2010, 5, 658-666.	1.1	18
17	Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 5003-5014.	7.0	16
18	Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611012.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Graphene Oxide-Facilitated Comprehensive Analysis of Cellular Nucleic Acid Binding Proteins for Lung Cancer. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 17756-17770.	8.0	14
20	Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. <i>Lung</i> , 2015, 193, 805-814.	3.3	13
21	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	1.8	13
22	Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. <i>Clinical and Experimental Immunology</i> , 2022, 208, 316-322.	2.6	13
23	Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry. <i>Oncotarget</i> , 2017, 8, 5487-5497.	1.8	11
24	The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. <i>Oncology Reports</i> , 2019, 41, 2636-2646.	2.6	10
25	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. <i>Journal of Molecular Medicine</i> , 2019, 97, 1657-1668.	3.9	7
26	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 634920.	2.8	7
27	Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 43-50.	2.0	2
28	Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100373.	1.7	2
29	Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100345.	1.7	2
30	Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19009-e19009.	1.6	1
31	A survival comparison study of Chinese patients with primary lung adenocarcinoma harboring ALK rearrangements with crizotinib treatment detected by FISH, IHC, and RT-PCR.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19135-e19135.	1.6	1